ERBB2 and melanoma: For example, the expansion of HER‐2, MAGE‐1, and GP100 in 4/9 patients and systemic cytotoxic response of peripheral blood mononuclear cells (PBMCs) in 6/10 patients when treated using DCs pulsed with whole water‐soluble tumor lysates.[180] In another clinical trial with 43 stage IV patients and 7 stage III melanoma patients, autologous DCs that were pulsed with a novel allogeneic water‐soluble cell lysate (TRIMEL) from three melanoma cell lines were used.